1744 related articles for article (PubMed ID: 32979476)
1. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
Khare P; Sahu U; Pandey SC; Samant M
Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
[TBL] [Abstract][Full Text] [Related]
2. Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CL
Mouffouk C; Mouffouk S; Mouffouk S; Hambaba L; Haba H
Eur J Pharmacol; 2021 Jan; 891():173759. PubMed ID: 33249077
[TBL] [Abstract][Full Text] [Related]
3. Effect of the Phytochemical Agents against the SARS-CoV and Some of them Selected for Application to COVID-19: A Mini-Review.
Idrees M; Khan S; Memon NH; Zhang Z
Curr Pharm Biotechnol; 2021; 22(4):444-450. PubMed ID: 32619167
[TBL] [Abstract][Full Text] [Related]
4. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
Akaji K; Konno H
Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
[TBL] [Abstract][Full Text] [Related]
5. Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL
Kumar V; Shin JS; Shie JJ; Ku KB; Kim C; Go YY; Huang KF; Kim M; Liang PH
Antiviral Res; 2017 May; 141():101-106. PubMed ID: 28216367
[TBL] [Abstract][Full Text] [Related]
6. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(7):571-596. PubMed ID: 33463470
[TBL] [Abstract][Full Text] [Related]
7. Roles of flavonoids against coronavirus infection.
Russo M; Moccia S; Spagnuolo C; Tedesco I; Russo GL
Chem Biol Interact; 2020 Sep; 328():109211. PubMed ID: 32735799
[TBL] [Abstract][Full Text] [Related]
8. Current Strategies of Antiviral Drug Discovery for COVID-19.
Mei M; Tan X
Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
[TBL] [Abstract][Full Text] [Related]
9. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.
Coleman CM; Sisk JM; Mingo RM; Nelson EA; White JM; Frieman MB
J Virol; 2016 Oct; 90(19):8924-33. PubMed ID: 27466418
[TBL] [Abstract][Full Text] [Related]
10. The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase.
Lung J; Lin YS; Yang YH; Chou YL; Shu LH; Cheng YC; Liu HT; Wu CY
J Med Virol; 2020 Jun; 92(6):693-697. PubMed ID: 32167173
[TBL] [Abstract][Full Text] [Related]
11. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
[TBL] [Abstract][Full Text] [Related]
12. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
13. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.
Mishra J; Prasun C; Sahoo PK; Nair MS
Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095
[TBL] [Abstract][Full Text] [Related]
14. Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19.
Faheem ; Kumar BK; Sekhar KVGC; Kunjiappan S; Jamalis J; Balaña-Fouce R; Tekwani BL; Sankaranarayanan M
Bioorg Chem; 2020 Nov; 104():104269. PubMed ID: 32947136
[TBL] [Abstract][Full Text] [Related]
15. Potential inhibitors of SARS-CoV-2: recent advances.
Jamalipour Soufi G; Iravani S
J Drug Target; 2021 Apr; 29(4):349-364. PubMed ID: 33210953
[TBL] [Abstract][Full Text] [Related]
16. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
17. Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19.
Anirudhan V; Lee H; Cheng H; Cooper L; Rong L
J Med Virol; 2021 May; 93(5):2722-2734. PubMed ID: 33475167
[TBL] [Abstract][Full Text] [Related]
18. Computational modeling of the bat HKU4 coronavirus 3CL
Abuhammad A; Al-Aqtash RA; Anson BJ; Mesecar AD; Taha MO
J Mol Recognit; 2017 Nov; 30(11):. PubMed ID: 28608547
[TBL] [Abstract][Full Text] [Related]
19. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
[TBL] [Abstract][Full Text] [Related]
20. Coronavirus Infection-Associated Cell Death Signaling and Potential Therapeutic Targets.
Yapasert R; Khaw-On P; Banjerdpongchai R
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]